Predictors of Internal Mammary Artery Graft Failure

The Internal Mammary Artery (IMA) is the preferred conduit for bypassing the left anterior descending artery (LAD) in patients undergoing coronary artery bypass grafting. There is no systematic evaluation of the frequency and predictors of IMA failure or long-term outcomes.

 

The PREVENT IV included 1539 patients receiving IMA-LAD revascularization with 12 and 18 month follow up. Logistic regression was used to identify characteristics associated with IMA failure (≥75% stenosis) and itsconnectionwith clinical events such as death, myocardial infarction, and repeat revascularization.

 

IMA failure occurred in 132 patients (8.6%). Predictors of IMA graft failure were LAD stenosis <75% (OR 1.76; CI 95% 1.19-2.59), additional bypass graft to diagonal branch (OR 1.92; CI 95% 1.33-2.76), and not having diabetes (OR 1.82; CI 95% 1.20-2.78).

 

IMA failure was associated with a higher incidence of AMI mostly due to a higher rate of repeat revascularization.

 

Conclusion
IMA failure is associated to clinical events and is observed mainly in patients with a prior intermediate LAD stenosis or with an additional bypass graft to a diagonal branch. This finding should be taken into account when indication surgery for patients with no functional evidence of ischemia in LAD territory.

 

Original Title: Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes: Insights From the PREVENT IV Trial. Reference: Ralf E. Harskamp et al. Circulation. 2015 Dec 8.Epub ahead of print.


Suscríbase a nuestro newsletter semanal

Reciba resúmenes con los últimos artículos científicos

Su opinión nos interesa. Puede dejar su comentario, reflexión, pregunta o lo que desee aquí abajo. Será más que bienvenido.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

T-TEER: Beyond Traditional Pulmonary Hypertension Thresholds

Significant tricuspid regurgitation (TR) is associated with progressive functional deterioration, heart failure (HF) hospitalizations, and increased mortality. In recent years, transcatheter tricuspid edge-to-edge repair...

Is left atrial appendage closure safe in patients with reduced ejection fraction?

Patients with heart failure with reduced ejection fraction (HFrEF) were excluded from the major randomized trials evaluating percutaneous left atrial appendage closure (LAAC), and...

Left Atrial Appendage Closure in Spain: Sustained Growth and Favorable Real-World Outcomes

Oral anticoagulation remains the standard treatment for stroke prevention in patients with atrial fibrillation. However, many patients have a high bleeding risk or contraindications...